Skip to main content
. 2023 Jan 31;41(9):1545–1549. doi: 10.1016/j.vaccine.2023.01.049

Fig. 1.

Fig. 1

Receptor-binding domain (RBD)-IgG dynamics in study participants (a) RBD-IgG dynamics in all the participants analyzed are shown. Geometric means and 95 % confidential intervals of RBD-IgG of each blood collection point are shown. The paired t-tests of logarithms of RBD-IgG titers revealed higher geometric mean RBD-IgG titer at 3 weeks, 8 weeks, and 6 months after the third dose comparing with the corresponding after the second dose, while the geometric mean RBD-IgG titer was the highest at 8 weeks after the second dose and at 6 months after the third dose. b) Difference in the geometric mean RBD-IgG between male (blue) and female (red) participants. Female participants demonstrated higher geometric mean RBD-IgG titer until 3 months after the second dose, while the geometric mean RBD-IgG titers were not different 6 months after the second dose (t-test of logarithms of the RBD-IgG titer). c) Difference in the geometric mean RBD-IgG between participants aged 50 years and older (orange) and participants younger than 50 years (blue). Younger participants demonstrated higher geometric mean RBD-IgG titer 3 weeks after the second dose, while the geometric mean RBD-IgG titers were not different 8 weeks after the second dose (t-test of logarithms of the RBD-IgG titer). Abbrrrreviations: RBD-IgG, anti-receptor binding domain IgG titer; wks, weeks; mos, months; aft, after; 2nd, administration of the second dose; 3rd, administration of the third dose.